NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.
BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.
NICE have recommended, in the draft guidance, that adjuvant ribociclib can only be used if the cancer is lymph-node positive and present in:
- at least 4 axillary lymph nodes, or
- 1 to 3 axillary lymph nodes and the cancer:
- is grade 3, defined as at least 8 points on the modified Bloom–Richardson grading system or equivalent, or
- has a primary tumour size of at least 5 cm
See the NICE TA information and more relevant papers/response below:
- 1 Recommendations | Draft guidance consultation | Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153] | Consultations | NICE
- committee-papers
- We respond to NICE decision to approve adjuvant ribociclib with aromatase inhibitor for only some patients who could benefit | Breast Cancer Now
